|
مقاله
|
Abstract
|
|
|
|
Title:
|
Combination of intravitreal Bevacizumab and Erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema; a randomized double-blind clinical trial
|
|
Author(s):
|
Morteza Entezari MD. Zahra Kiani Flavarjani MD. Alireza Ramezani MD. Humayon Nikkhah MD. Saeed Karimi MD. Hamid Fateh Moghadam MD. Narsis Daftarian MD. Mehdi Yaseri, PhD.
|
|
Presentation Type:
|
Oral
|
|
Subject:
|
Posterior Segment
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Morteza Entezari
|
|
Affiliation :(optional)
|
1. Ophthalmic Research Center, Department of Ophthalmology, Imam Hossein Medical Center, Shahid Beheshti Medical Sciences, Tehran, Iran
|
|
E mail:
|
entmort@hotmail.com
|
|
Phone:
|
22816770
|
|
Mobile:
|
09121248273
|
|
|
|
|
Purpose:
|
To evaluate the effect of three intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal erythropoietin (EPO) in the treatment of refractory diabetic macular edema (DME).
|
|
Methods:
|
In a randomized double-blind clinical trial, 48 eyes of 34 diabetic patients with refractory DME were enrolled. Eyes were randomly assigned to receive either 3 monthly injections of 0.05 cc (1.25mg) IVB plus 0.05 cc (1000 Unit) EPO or 0.05 cc (1.25mg) IVB alone. Main outcome was best-corrected visual acuity (BCVA) changes and secondary outcome was central macular thickness (CMT). The patients were followed for 6 months.
|
|
Results:
|
Mean BCVA changes up to 4 and 6 months were insignificant in both groups. It changed from 0.72±0.56 logMAR at baseline to 0.74±0.5 (P=0.85) and 0.71±0.44 (P=0.40) in the combination group and from 0.48±0.39 logMAR to 0.47±0.35 (P=0.48) and 0.52±0.33 (P=0.69) in the IVB alone group, at 4 and 6 months, respectively. The difference of mean BCVA changes between the groups were insignificant at both 4 and 6 months (P=0.07 and P=0.36, respectively). Within the group changes of mean CMT were significant only in the combination group at 4 and 6 months, from 518±134µ at baseline to 472±151 to 475±167µ, respectively (P=0.01 and P=0.05). Corresponding changes were not significant in the IVB alone group. However, the difference between the groups was not significant at all visits (P=0.51 and P=0.71, respectively).
|
|
Conclusion:
|
This clinical trial demonstrated that intravitreal erythropoietin had no additional effect to IVB in the treatment of refractory DME in short term.
|
|
Attachment:
|
|
|
|